Supported by Astellas Pharma Inc., Japan, through financial grants, whereby each participating study site (not individual site investigators) received fixed-part reimbursement for every patient enrolled, covering the additional costs of the trial.
Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis†
Article first published online: 1 SEP 2011
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 18, Issue 5, pages 803–808, May 2012
How to Cite
Ogata, H., Kato, J., Hirai, F., Hida, N., Matsui, T., Matsumoto, T., Koyanagi, K. and Hibi, T. (2012), Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis, 18: 803–808. doi: 10.1002/ibd.21853
- Issue published online: 12 APR 2012
- Article first published online: 1 SEP 2011
- Manuscript Accepted: 13 JUL 2011
- Manuscript Received: 24 MAR 2011
- 6Differential diagnosis of chronic ulcerative colitis and Crohn's disease. In: Kirsner JB, ed. Inflammatory Bowel Disease, 5th ed. Philadelphia: W.B. Saunders; 2000: 315–325., , .
- 11Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease — a long-term follow-up. Am J Gastroenterol. 2006; 101: 1048–1056., , , et al.Direct Link: